Carcinoma of the prostate is one of the most common cancers in men over 50 years of age and is the second leading cause of cancer death in men over 75. As a general rule, symptoms usually are not apparent until the tumor is far advanced. Between 80 to 90 percent of patients have metastatic disease at the time of presentation and are not curable by surgery. Endocrine manipulation remains the most effective and commonly used treatment for metastatic carcinoma of the prostate.
RubinP, ed. Clinical oncology for medical students and physicians—a multidisciplinary approach. 6th ed.Rochester, NY: American Cancer Society, 1983: 210–9.
2.
De KernionJB. Cancer of the prostate. In: HaskellCM, ed. Cancer treatment. Philadelphia: WB Saunders, 1985: 352–66.
3.
KasimisBSMillerJBKaneshiroCAForbesKAMoranEMMetterGE. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C(FAM‘) in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial. J Clin Oncol1985; 3: 385–92.
PerezCARairWRIbdeDCLabrieF. Cancer of the prostate. In: DevitaVTJrHellmanSRosenbergSA, eds. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1985: 929–64.
6.
Del RegatoJASpjutHJCoxJD, eds. Cancer: diagnosis, treatment, and prognosis. St. Louis: CV Mosby, 1985: 681–705.
7.
HerrHWYagodaA. Neoplasms of the kidney, bladder, and prostate. In: CalabresiPScheinPSRosenbergSA, eds. Medical oncology. New York: Macmillan, 1986: 1064.
8.
Von EschenbachAC. Cancer of the prostate. Curr Prob Cancer1981; 5: 3–54.
9.
WhiteheadEDLeiterE. Prostate carcinoma. NY State J Med1981; 81: 184–93.
10.
SherPP. Drug interactions with clinical laboratory tests. Drugs1982; 24: 24–63.
11.
EvansNBarnesRWBrownAF. Carcinoma of the prostatecorrelation between the histologic observations and the clinical course. Arch Pathol1942; 34: 473–83.
12.
PoolTLThompsonGJ. Conservative treatment of carcinoma of the prostate. JAMA1956; 160: 833–7.
13.
CorriereJNCornogJLMurphyJJ. Prognosis in patients with carcinoma of the prostate. Cancer1970; 25: 911–8.
14.
HanashKAUtzDCCookENTaylorWFTitusJL. Carcinoma of the prostate: a 15-year followup. J Urol1972; 107: 450–3.
15.
HovsepianJAByarDP. Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: correlation between radiologic quantitation of metastases and patient survival. Urology1975; 6: 11–6.
16.
WhiteheadED. Management of prostate carcinoma. NY State J Med1981; 81: 1481–5.
17.
GellerJAlbertJD. Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol1983; 10 (suppl 4): 34–41.
18.
HugginsCHodgesCV. Studies on prostatic cancer. I: The effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res1941; 1: 293–7.
19.
CoffeyDSIsaacsJF. Control of prostate growth. Urology1981; 17 (suppl): 17–24.
20.
SantenRJWarnerB. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of the prostate. Urology1985; 25 (2 suppl): 53–7.
WinfieldHTrachtenbergJ. A comparison of powerful luteinizing hormone releasing hormone analogue anonist and estrogen in the treatment of advanced prostatic cancer. J Urol1984; 131: 1107–9.
23.
VanceMASmithJA. Endocrine and clinical effects of leuprolide in prostatic cancer. Clin Pharmacol Ther1984; 36: 350–3.
24.
SmithJAJrGlodeLMWettlauferJNClinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate. Urology1985; 25: 106–14.
25.
TortiFM. Hormonal therapy for prostate cancer. N Engl J Med1984; 311: 1313–4.
26.
BailarJCByarDP. Veterans Administration Cooperative Urological Research Group. Estrogen treatment for cancer of the prostate. Cancer1970; 26: 257–61.
27.
ByarDP. Veterans Administration Cooperative Urological Research Group. Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol1972; 108: 908–13.
28.
ByarDP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer1973; 32: 1126–30.
29.
SmithPH. Endocrine and cytotoxic therapy. Recent results. Cancer Res1981; 78: 154–72.
30.
Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med1984; 311: 1281–6.
31.
Leuprolide acetate (Lupron). TAP Pharmaceuticals, North Chicago, IL, 1985.
YamanakaJMarinoTYajimaHKazuhisaSShidaK. Efficacy of (D-Leu6)-DES GLY-NH210-LHRH ethylamide against prostatic cancer. Prostate1985; 6: 27–34.
34.
SantenRJDemersLMMaxDTSmithJSteinBSGlodeLM. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab1984; 58: 397–400.
35.
KahanADelrieuFAmorBChicheRStegA. Disease flare induced by D-Trp6-LHRH analogue in patients with metastatic prostatic cancer. Lancet1984; 1: 971–2.
36.
SmithJA. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol1984; 131: 1110–2.
37.
WaxmanJ. Hormonal aspects of prostatic cancer: a review. J R Soc Med1985; 78: 129–35.
38.
MurrayRPittP. Treatment of advanced prostatic cancer resistant to conventional therapy with aminoglutethimide. Eur J Cancer Clin Oncol1985; 21: 453–8.
39.
BlockMTrumpDRoseDPCummingsKBHoganTF. Efficacy of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy. Cancer Treat Rep1984; 68: 719–22.
40.
PonderBAJShearerRJPocockRDResponse to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer1984; 50: 757–63.
41.
DracoJRSantenRJLiptonAClinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer1984; 53: 1447–50.
42.
JacobiGHSchmidtJDWeinsteinSHFlocksRH. Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic carcinoma. Urology1976; 8: 231–3.
43.
SoganiPCVagaiwalaMBWhitmoreWF. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer1984; 54: 744–50.
44.
MacfarlaneJRTolleyDA. Flutamide therapy for advanced prostatic cancer: a phase II study. Br J Urol1985; 57: 172–4.
45.
JacobiGHAltweinJEKurthKHBastingRFellnerR Hohen. Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomized trial. Br J Urol1980; 52: 208–15.
46.
BanomiPPessisDBuntingNMegestrol acetate used as primary hormonal therapy in stage D prostate cancer. Semin Oncol1985; 12 (suppl 1): 36–9.
AllenJMKerleDJWareHDobleAWilliamsGBloomSR. Combined treatment with ketoconazole and luteinizing hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. Br Med J1983; 287: 1766.
49.
WalterYOswaltJSolowayMS. Estramustine phosphate—hormone, chemotherapeutic agent, or both?Urology1984; 24: 53–8.
50.
TannockIF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?J Clin Oncol1985; 3: 1013–21.
